Diluted EPS came in at $-1.24 (+9.5% YoY), missed the $-1.16 consensus by $0.08.
Trailing eight quarters through Q1 2026
Common questions about Forte Biosciences's Q1 2026 earnings report.
Forte Biosciences (FBRX) reported Q1 2026 earnings on May 11, 2026 after market close.
Forte Biosciences reported diluted EPS of $-1.24 for Q1 2026.
EPS missed the consensus estimate of $-1.16 by $0.08.
Compared to the same quarter a year prior, diluted EPS grew 9.5% from $-1.37.
You can read the 10-K periodic report (0001193125-26-134498) directly on SEC EDGAR. The filing index links above go to sec.gov.